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PyruvateThe mitochondrial aspartate-glutamate carrier isoform 2 (citrin) and mitochondrial glycerol-3-phosphate dehy-
drogenase (mGPD) double-knockout mouse has been a useful model of human citrin deﬁciency. One of the most
prominent ﬁndings has beenmarkedly increased hepatic glycerol 3-phosphate (G3P) following oral administra-
tion of a sucrose solution. We aimed to investigate whether this change is detectable outside of the liver, and to
explore themechanismunderlying the increasedhepatic G3P in thesemice.WemeasuredG3P and itsmetabolite
glycerol in plasma and urine of themice under various conditions. Glycerol synthesis from fructosewas also stud-
ied using the liver perfusion system. The citrin/mGPD double-knockout mice showed increased urine G3P and
glycerol under normal, fed conditions. We also found increased plasma glycerol under fasted conditions, while
oral administration of different carbohydrates or ethanol led to substantially increased plasma glycerol. Fructose
infusion to the perfused liver of the double-knockout mice augmented hepatic glycerol synthesis, and was ac-
companied by a concomitant increase in the lactate/pyruvate (L/P) ratio. Co-infusion of either pyruvate or phen-
azine methosulfate, a cytosolic oxidant, with fructose corrected the high L/P ratio, leading to reduced glycerol
synthesis. Overall, these ﬁndings suggest that hepatic glycerol synthesis is cytosolic NADH/NAD+ ratio-lutamate carrier;Ala, alanine; AOA, aminooxyacetate; Arg, arginine; ASA, argininosuccinate;Asp, aspartate; Cit, citrulline;CTLN2,
droxyacetonephosphate;Gln,glutamine;Glu, glutamate;G3P, glycerol3-phosphate;KO,knockout; Lac, lactate;L/P ratio, lactate-
ochondrial glycerol-3-phosphate dehydrogenase; Na-Pyr, sodiumpyruvate; NICCD, neonatal intrahepatic cholestasis caused by
ate;wt, wild-type
ject, Institute of ResourceDevelopment andAnalysis, KumamotoUniversity, 2-2-1Honjo, Kumamoto 860-0811 Japan. Tel.:+81
1788 M. Moriyama et al. / Biochimica et Biophysica Acta 1852 (2015) 1787–1795dependent and reveal a likely regulatorymechanism for hepatic glycerol synthesis following a high carbohydrate
load in citrin-deﬁcient patients. Therefore, urine G3P and glycerolmay represent potential diagnosticmarkers for
human citrin deﬁciency.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Human citrin (encoded by SLC25A13) is a liver-type mitochondrial
aspartate-glutamate carrier (AGC isoform 2; AGC2) [1,2], and was ini-
tially found to be deﬁcient in the autosomal recessive disease, adult-
onset type II citrullinemia (CTLN2) [3] — a disorder characterized by
late-onset and recurring symptoms of abnormal behavior and sudden
disturbances of consciousness due to hyperammonemia. SLC25A13mu-
tations have also now been identiﬁed in cholestatic infants with tran-
sient multiple aminoacidemias, galactosemia and hypoproteinemia
with growth failure (designated neonatal intrahepatic cholestasis
caused by citrin deﬁciency; NICCD) [4–6]. Further examination of
known patients outside of the neonatal period has also found persistent
failure to thrive and dyslipidemia [7]. In total, the age-dependent clini-
cal spectrum that characterizes the collective disease entity called citrin
deﬁciency (a.k.a., AGC2 deﬁciency) has now been established [8–10].
In spite of the clear relationship between SLC25A13 mutations
and the various age-speciﬁc presentations, the ﬁrst mouse model of
citrin deﬁciency, the Slc25a13 knockout (KO) mouse, showed virtually
no physiological consequences despite measurable in vitro biochemical
abnormalities [11]. Considering the two classical pathways for
transporting cytosolic NADH reducing equivalents into the mitochon-
dria, the malate-aspartate (Asp) and glycerophosphate shuttles (both
demonstrated to be highly active in rodent liver), we have created an
improved citrin-deﬁcient mouse model that exhibits a variety of
CTLN2 and NICCD phenotypes. By crossing the citrin-KO mouse with
the Gpd-2 (encoding mitochondrial glycerol-3-phosphate dehydroge-
nase; mGPD)-KO mouse [12], the citrin/mGPD double-KO mice exhibit
symptoms of growth retardation, hypoglycemia, and hyperammonemia
under fed conditions that are exaggerated by oral administration of a
sucrose solution [12]. The double-KO mice also show loss of body
weight when fed a high carbohydrate diet (AIN-93 M) due to reduced
intake, while they recover their body weight when they are switched
to a higher protein diet, or one enriched with amino acids, sodium
pyruvate (Na-Pyr) or medium-chain triglycerides (MCT) [13]. A
metabolomic analysis of the citrin/mGPD double-KO mice further re-
vealed a variety of changes in hepaticmetabolites following oral admin-
istration of sucrose: marked elevations of glycerol 3-phosphate (G3P)
and citrulline (Cit), inhibition of lysine metabolism resulting in in-
creased lysine, and decreased TCA cycle intermediates alongwith gluta-
mate (Glu) and glutamine (Gln) [14]. Furthermore, these metabolite
changes could be ameliorated by the simultaneous administration of
Na-Pyr, amino acids including alanine (Ala) and Glu, or MCT [13].
The purpose of the present study was to examinewhether we could
ﬁnd evidence of the hepatic changes observed in the citrin/mGPD
double-KO mice in plasma or urine, especially the marked increase in
G3P, that would serve as either diagnosis markers, or potential thera-
peutic outcome measures, of citrin deﬁciency. The double-KO mice do
in fact show increased urine G3P and glycerol under fed conditions,
and increased plasma glycerol under fasted conditions as well as after
oral administration of various carbohydrates. We further explored the
effect of a carbohydrate load on hepatic glycerol synthesis in the
double-KOmice using the liver perfusion system to testwhether elevat-
ed urine and plasma glycerol are derived from liver metabolism. The
presence of fructose in the perfusate of the double-KO mice led to in-
creased hepatic glycerol production that was coupled to the elevated
lactate/pyruvate (L/P) ratio, revealing that hepatic glycerol synthesis is
dependent on the cytosolic NADH/NAD+ ratio. Finally, our examina-
tions of urine from citrin-deﬁcient patients revealed, for the ﬁrst time,a subset of them have increased urine glycerol and G3P levels. Overall,
our ﬁndings implicate urine G3P and glycerol as potential markers of
citrin deﬁciency.
2. Materials and methods
2.1. Materials
Fructose was purchased from Merck Co. (Darmstadt, Germany).
Glucose, ethanol (99.5%), L-Ala, Na-Pyr and phenazine methosulfate
(PMS) were obtained from Wako Pure Chemical Co. (Osaka, Japan).
Aminooxyacetate (AOA) was obtained from Sigma-Aldrich Corp.
(St. Louis, MO, USA). Difco Bacto Tryptone was supplied from Voigt
Global Distribution Inc. (Lawrence, USA). Enzymes formetabolite deter-
minationwere obtained fromRocheDiagnostics (Indianapolis, IN, USA).
Other reagents were of analytical grade.
2.2. Animals
All wild-type (wt), citrin-KO,mGPD-KO and citrin/mGPDdouble-KO
mice used were congenic on the C57BL/6 J background. Mice used for
the experiments were generated using the breeding scheme described
previously by Saheki et al. [14]. Brieﬂy, mGPD-KO and double-KO mice
were obtained by mating heterozygous citrin-KO/homozygous mGPD-
KO (citrin+/−/mGPD−/−) mice, while wt and citrin-KO mice were gen-
erated by mating heterozygous citrin-KO (citrin+/−/mGPD+/+) mice.
Genotyping was performed with DNA extracted from ear punches
using procedures speciﬁc for each of the targeted mutations in the
citrin-KO [11] and mGPD-KO [15] mice, respectively. All mice were
maintained at a constant temperature (23 ± 1 °C) on a 12-hour light/
dark cycle (light on, 8:00 to 20:00) with free access to water and CE2
chow (25% protein, 4.6% fat, and 50% carbohydrate providing 343 kcal/
100 g; CLEA Japan, Tokyo, Japan). The experimental protocols met the
institution's and the National Research Council's standards for the care
and use of laboratory animals in research and were approved by the
Ethical Committees for Animal Experimentation at KumamotoUniversi-
ty (B25-147) and Osaka Prefecture University (22-2).
2.3. Sample preparation
Mice used for the experiments were analyzed between 80 and
160 days of age. Urine was collected overnight (between 18:00
and +9:00) from singly-housed mice in metabolic cages (Natsume
Seisakusho Co., Ltd., Tokyo, Japan)with CE-2 chowunder fed conditions,
or 24 h without chow under fasted conditions. Plasma was separated
from blood taken from the heart of mice under sodium pentobarbital
(50 mg/kg body weight) anesthetic between 10:00 and 11:00, 1 h
after administration of a solution by gastric tube. Solutions administered
were sucrose, glucose, fructose, ethanol, or sucrose containing tryptone,
Na-Pyr, Ala, orMCT. In separate experiments, following cervical disloca-
tion, livers were quickly removed, freeze-clamped between aluminum
tongs, and stored at−70 °C for analysis of G3P.
2.4. Contents of test solutions
Solutions administered were 20 ml/kg of 25% sucrose (5 g/kg),
25% glucose (5 g/kg), 25% fructose (5 g/kg), 9% (vol/vol) ethanol
(1.4 g/kg), or 25% sucrose containing 25% tryptone (5 g/kg), 1 M Na-Pyr
(20 mmol/kg), 1 M Ala (20 mmol/kg), or 5% MCT (contained 78.9%
1789M. Moriyama et al. / Biochimica et Biophysica Acta 1852 (2015) 1787–1795MCT consisting of 56% caprylic acid and 44% capric acid) (Kissei Pharma-
ceutical Co. LTD., Matsumoto, Japan).2.5. Liver perfusion
Mice were fasted for 24 h, and the liver was perfused as described
previously [16]. After eachmousewas anesthetizedwith sodiumpento-
barbital (0.05 mg/g of body weight), the portal vein and inferior vena
cava were cannulated, and the liver was perfused in situwith oxygenat-
ed Krebs–Henseleit bicarbonate buffer (pH 7.4, 37 °C, saturated with
95% O2–5% CO2) using a ﬂow-through method. The liver was perfused
at a constant ﬂow rate of approximately 8 ml/min. In each experiment,
the liverwasperfused for 30min in the absence of exogenous substrates
before various substrates were added. The oxygen concentration was
continuouslymonitored in the perfusate using a Clark-typeO2 electrode
after passage through the liver, and samples were collected for speciﬁc
measurements at indicated times. At the end of perfusion, the liver
was freeze-clamped in liquid nitrogen and stored at−70 °C for analysis
of metabolites.1000 
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*2.6. Collection of human urine
Urine specimens were obtained from human controls and citrin-
deﬁcient patients ranging between 1 month and 72 years of age. For
neonates and infants less than one year of age, sample collection was
generally at an unspeciﬁed time of day, and irrespective of fed or fasted
state. Samples from controls and patients older than 1 year of age repre-
sented ﬁrst morning voids that were collected within 1 h of waking
following an overnight fast. The mutations identiﬁed in the 37 patients
were 851del4 (37 alleles), IVS11 + 1G N A (18), 1638ins23 (2),
IVS16ins3kb (4), S225X (1), IVS13 + 1G N A (1), IVS6 + 5G N A (1),
IVS7-2A N G (1), E601X (2), Q259X (1), R588Q (1), Q357R (1), and
Y500D (1). In three patients, no second mutation was identiﬁed. Writ-
ten informed consent was received from participants or their parents
prior to inclusion in the study. This experiment was approved by the
Committee for Ethics, Kumamoto University (No. 1652) under the title
of “Diagnostic evaluation of urinary glycerol for citrin deﬁciency”.0 
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Fig. 1. Urine G3P (A and C) and glycerol (B and D) levels under fed (A and B) and fasted
(C and D) conditions. Urine G3P and glycerol are expressed in nmol per mg Cr, with
data from each genotype being shown as a box-and-whisker plot, and the number of
mice examined indicated inparentheses. Outlier values are shown as an ‘X’. Signiﬁcant dif-
ferences between genotypes are indicated (*p b 0.05, **p b 0.01).2.7. Analytical procedures
The hepatic concentration of G3P was determined using enzymatic
methods with NAD+ [17]. The concentrations of glycerol in the perfus-
ate, and of glycerol and G3P in the urine were quantiﬁed enzymatically
[18]. Urine levels of G3P and glycerol are expressed as nmol permg cre-
atinine (Cr), which was determined using the Aqua-auto CRE-II Test Kit
(KAINOS Laboratories, Inc., Tokyo, Japan). Since plasma G3P was below
the limit of detection using the enzymatic method, plasma glycerol was
determined with a commercially-available direct colorimetric assay
using glycerol kinase, peroxidase and glycerol phosphate oxidase
(Randox Laboratories, Ltd., London, UK). The concentration of glucose
in the perfusate was assayed using the Glucose CII test (Wako kits,
Wako Pure Chemical Industries, Osaka, Japan). The concentrations of
lactate (Lac) and pyruvate (Pyr) in the perfusate and liver were quanti-
ﬁed enzymatically by previously published methods, respectively
[19,20]. The hepatic concentrations of dihydroxyacetone phosphate
(DHAP), citrate, malate and α-ketoglutarate (αKG) were determined
using established enzymatic methods [21–24]. We calculated the per-
fusate L/P ratio, and the rate of Lac-plus-Pyr production by the liver
from the concentrations of efﬂux Lac and Pyr. Hepatic amino acids
were determined by LC/MS/MS (Acquity UPLC/TQD; Waters, Milford,
MA, USA) after solid phase extraction followed by derivatization [25]
using the EZ:faast Amino Acid Analysis kit (Phenomenex Ltd., Los
Angeles, CA, USA).2.8. Statistical analysis
Urine G3P and glycerol levels are represented as box-and-whisker-
plots following the establishment of group quartiles, interquartile
range (ICR) and determination of outliers (based on greater than 1.5
times ICR) using Excel for Mac 2011 (Microsoft, Redmond,Washington,
USA). Statistical comparisons of urine levels between genotypes or
treatment groups were performed by the Mann–Whitney U test using
JMP 9 software (SAS Institute Inc., Cary, North Carolina, USA). Data are
expressed as means ± SEM. Statistical analysis was performed by a
one-way analysis of variance (ANOVA) followed by Tukey–Kramer or
Scheffé's F test for multiple comparisons. For comparison of two groups,
a Student's t-testwasused. A p value of b0.05was considered statistical-
ly signiﬁcant for all tests performed.
3. Results
3.1. Urine G3P and glycerol in mice
To determine if we could detect evidence of the increased hepatic
G3P observed previously in the citrin/mGPD double-KO mice [14] out-
side of the liver, we measured urine G3P and glycerol. The results are
shown as box-and-whisker plots (Fig. 1). The double-KO mice showed
increased median concentrations of both urine G3P (Fig. 1A) and urine
glycerol (Fig. 1B) under fed conditions when compared to the other ge-
notypes,while themGPD-KOmice showed intermediate G3P levels that
were statistically different from wt and citrin-KO mice. On the other
hand, there was no difference in urine G3P levels (Fig. 1C) among the
mouse genotypes under fasted conditions, while urine glycerol was
1790 M. Moriyama et al. / Biochimica et Biophysica Acta 1852 (2015) 1787–1795signiﬁcantly elevated in the double-KO mice when compared to the
other genotypes (Fig. 1D). Correlation coefﬁcients between urine glyc-
erol and urine G3P levels in the double-KO mice were found not to be
statistically signiﬁcant (R = 0.389 and −0.184 under fed and fasted
conditions, respectively).
3.2. Effect of carbohydrates and ethanol on plasma glycerol in mice
Next, we determined the plasma G3P concentration in the mice
using an alternative method (as the levels were below detection using
the original method; see Materials and methods section). There were
no differences in plasma glycerol levels among the genotypes under
fed conditions (Fig. 2A) despite the increased urinary G3P and glycerol
levels found in the double-KO mice (and intermediate urine G3P levels
in themGPD-KOmice; Fig. 1A, B). Under fasted conditions, however, the
plasma glycerol level in the double-KO mice was signiﬁcantly higher
compared to the other genotypes (Fig. 2B).
Using mice under fed conditions, we orally administered a 25% su-
crose solution that had previously been shown to increase hepatic G3P
in the double-KO mice [13,14], and this also led to increased plasma
glycerol levels speciﬁcally in the double-KO mice (Fig. 2C). Using solu-
tions of either of the two monosaccharides that comprise sucrose, glu-
cose (Fig. 2D) or fructose (Fig. 2E), alone caused increased plasma
glycerol in the double-KOmice. Fructose caused a similar glycerol eleva-
tion to sucrose, while the glycerol elevation due to the glucose solution
was relatively more modest, but still statistically different compared to
saline treatment. Oral administration of 9% ethanol, which is known to
generate cytosolic NADH from alcohol dehydrogenase, also increased
plasma glycerol in the double-KO mice as well as the mGPD-KO mice,
but not in wt or citrin-KO mice (Fig. 2F).
3.3. Effect of test solutions on sucrose-induced plasma glycerol in mice
Solutions of Na-Pyr, tryptone (derived from a pancreatic casein hy-
drolysate), Ala andMCT have all previously been shown to signiﬁcantly0 
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examined is indicated in parentheses.decrease hepatic G3P when simultaneously administered with sucrose
in the double-KOmice [13]. Similarly, simultaneous oral administration
of Na-Pyr, tryptone or Ala with sucrose signiﬁcantly decreased plasma
glycerol levels in the double-KOmice (Fig. 2G), whileMCT had no effect
on plasmaglycerol despite havingbeen shownpreviously to have a sup-
pressive effect on hepatic G3P levels in double-KO mice [13].
Although we did not measure the hepatic G3P and plasma glycerol
levels within the same mice, a highly statistically signiﬁcant correlation
(R = 0.953; p b 0.001) was found between the mean hepatic G3P and
plasma glycerol levels amongst the mouse genotypes and test solution
groups examined (Supplementary Fig. 1).
3.4. Effects of fructose on glycerol synthesis and L/P ratio in the
perfused liver
Since there appeared to be a strong association between hepatic G3P
and plasma glycerol levels in the double-KOmice, we wanted to deter-
mine the extent to which hepatic glycerol synthesis contributed to the
increased plasma and urine glycerol levels by using the liver perfusion
system. We chose fructose as a substrate for the perfused liver because
sucrose is known to be hydrolyzed into fructose and glucose in the ep-
ithelium of small intestine, after which both monosaccharides are
absorbed into the portal vein. Unlike glucose, however, where only a
portion is phosphorylated and metabolized within the liver, the major-
ity of fructose in the portal vein is phosphorylated and metabolized
within the liver, independent of hormonal regulation [26].
Fig. 3A shows the time course of glycerol synthesis from fructose in
the perfused liver. The substrate concentration of 5 mMwas chosen be-
cause fructose concentration in the portal system may reach 1–3.5 mM
in rats [27] as well as man [28], with the Km of human fructokinase
being ~0.8mM [29]. Although the addition of fructose slightly increased
the hepatic glycerol production inwt and citrin-KOmice, when fructose
was perfused through the livers of mGPD-KO and double-KO mice, a
dramatic increase in glycerol production was observed in both geno-
types. The increase in hepatic glycerol synthesis of the mGPD-KO(4) (6) (9) (7) (4) (6) (9) (6) (6) 6) (5) (6) (4) (8) (5) 
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10 min, while glycerol synthesis remained constant during the entire
time course of fructose infusion in the double-KO mice.
The sustained glycerol synthesis in the double-KO mouse was
coupled to a concomitant rise in the L/P ratio, which is a surrogate mea-
sure of the cytosolic NADH/NAD+ ratio (Fig. 3B). Nodifference in the L/P
ratio was seen among wt, cirtin-KO or mGPD-KO mice. These results
suggest that NADH reducing equivalents accumulating in the cytosol
of the double-KO mice may lead to sustained glycerol production.
We next determined the fate of the carbon skeleton during fructose
metabolism as it can bemetabolized to either glucose for gluconeogen-
esis [26,30] or Lac and Pyr for hepatic ATP synthesis [30], depending on
nutritional state. Fructose infusion gradually increased the rate of glu-
cose production (the rate was distinctly slower in the mGPD-KO mice)
and reached a steady state within 10 min in all mouse genotypes
(Fig. 3C). The rate of production of Lac-plus-Pyr, considered to be an
index of glycolysis, increased in the early phase of fructose infusion in
the mGPD-KO mice compared to wt and citrin-KO mice (Fig. 3D), and
during this time, oxygen consumption (which representsmitochondrial
electron transport chain activity) was signiﬁcantly inhibited (Fig. 3E).
After 20 min of fructose infusion, both the rate of Lac-plus-Pyr produc-
tion and oxygen consumption reached similar levels among the four
mouse genotypes. Although the mGPD-KO mice showed a distinct re-
sponse, the overall results suggest that the fructose-induced, sustained
hepatic glycerol production in the double-KO mice does not result
from activated fructose metabolism.To further evaluate whether the cytosolic NADH/NAD+ ratio is di-
rectly responsible for the sustained hepatic glycerol production in the
double-KOmice,we examined the effects of Pyr and PMS, a cytosolic ox-
idant [31], on the rate of glycerol synthesis. Addition of Pyr to the per-
fusate immediately re-oxidized cytosolic NADH, as indicated by the
decreased L/P ratio (Fig. 4B). This led to a dramatic decrease in the
rate of glycerol synthesis in the livers of double-KO mice over time
(Fig. 4A). Similarly, administration of PMS also lowered the L/P ratio
and led to a dramatic decrease in hepatic glycerol synthesis in the
double-KO mice.
To conﬁrm that the effects of perfusing Pyr or PMS with fructose
were due solely to lowering the cytosolic NADH/NAD+ ratio in the livers
of the double-KO mice, we examined the effects of inhibiting the
malate-Asp shuttle in fructose-perfused livers of mGPD-KOmice. Addi-
tion of AOA, a known inhibitor of transaminases [32], increased the L/P
ratio and led to an accompanied increase in the rate of glycerol synthesis
in the livers of mGPD-KO mice (Fig. 4C and D). These results conﬁrm
that glycerol synthesis from carbohydrates such as fructose is stimulat-
ed primarily as a result of an elevated NADH/NAD+ ratio owing to lim-
ited re-oxidation of cytosolic reducing equivalents in the livers of the
double-KO mice.
3.5. Changes in hepatic metabolites in the perfused liver
Analysis of hepatic levels of glycerol's precursors, G3P and the G3P/
DHAP ratio (no signiﬁcant differences in DHAP were observed) showed
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to the other three genotypes before (preperfusion) and after fructose
perfusion (Supplementary Fig. 2A–C). These results conﬁrm that the in-
creased cytosolic NADH/NAD+ ratio in the double-KO mice leads to in-
creased G3P production during fructose metabolism.
The analysis of intrahepatic levels of urea cycle intermediates detect-
ed greater levels of Cit, argininosuccinate (ASA), and arginine (Arg), and
lower level of Asp after fructose perfusion in the livers of double-KO
mice compared to wt mice (Supplementary Fig. 3). Hepatic Ala, Glu
and Gln were found to be increased following fructose administration
in all genotypes, although the increase was least pronounced in
double-KO mice when compared to wt (Supplementary Fig. 4). Similar
ﬁndings were also observed for TCA cycle intermediates (citrate, αKG,
malate); the increase in the double-KO mice was less pronounced
than those of the other genotypes (Supplementary Fig. 5).
The administration of Pyr after fructose perfusion normalized hepat-
ic G3P found in the double-KOmice, correcting the increased G3P/DHAP
ratio to that of the other genotypes (Supplementary Fig. 2A–C). Further-
more, the relatively increased Cit, ASA and Arg, and decreased Asp, Ala,
Glu, Gln, citrate, αKG and malate also largely normalized to levels sim-
ilar to those observed in wt mice (Supplementary Figs. 3–5). These re-
sults further conﬁrm that Pyr has multiple effects to normalize the
hepatic metabolite derangements observed in the double-KO mice.
3.6. Urine G3P and glycerol in patients with citrin deﬁciency
These ﬁndings in the double-KO mice prompted us to preliminarily
examine the urine levels of G3P and glycerol in samples from human
control subjects and citrin-deﬁcient patients. Since both urine G3P and
glycerol levels in control subjects were age-dependent, we divided
both sets of samples into three age groups: 0–11 months, 1–9 years
and over 10 years. Fig. 5 shows statistically signiﬁcant differences inboth urine G3P (Fig. 5C) and glycerol (Fig. 5D) between control and
citrin-deﬁcient patients in the 1–9 year old age group. Furthermore, in
the 0–11month old age group,ﬁve out of the 14 citrin-deﬁcient patients
(plus one citrin-deﬁcient patient sample judged to be outliers) showed
higher levels of urine glycerol (Fig. 5B) compared to the maximum
value of the control sample range (407 nmol/mg Cr; however, one con-
trol sample was also considered an outlier). There were no differences
found in either urine G3P or glycerol between control and citrin-
deﬁcient patients in the over 10-year-old age group.
4. Discussion
We have clearly shown that increased levels of G3P, or its related
metabolite glycerol, can be found in both plasma and urine of citrin/
mGPD double-KO mice. Moreover, we have revealed that fructose in-
creases hepatic glycerol synthesis in a cytosolic NADH/NAD+ ratio-
dependent manner in our citrin deﬁciency mouse model using the
liver perfusion system. Although preliminary examination showed
that urine glycerol and G3P levels from citrin-deﬁcient patients were
only signiﬁcantly higher in the 1–9 years old age group compared
to controls, these metabolites still may be potential and readily-
detectable markers of human citrin deﬁciency.
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we found in the double-KO mice under different nutritional states sug-
gests a distinction between the tissue of origin and the substrate(s) of
the G3P and glycerol. Under fed conditions, glycolysis in the liver is
rate limiting in the double-KO mice due to a high cytosolic NADH/
NAD+ ratio that inhibits glyceraldehyde-3-phosphate dehydrogenase,
leading to the buildup of DHAP that is shunted to G3P. The majority of
the increased G3P and glycerol in the urine of the double-KO mice
under fed conditions is most likely originating from the kidney, as plas-
ma glycerol was not signiﬁcantly increased in the double-KOmice. Only
after further exacerbation of fed double-KOmice with oral sucrose, glu-
cose, fructose or ethanol did the level of plasma glycerol increase. Fur-
thermore, simultaneous oral administration of tryptone, Ala or Na-Pyr
with sucrose suppressed the elevated plasma glycerol in the double-
KO mice (similar to previous ﬁndings that showed suppression of the
increased hepatic G3P [13]) by lowering the cytosolic NADH/NAD+
ratio. These latter ﬁndings also support the notion that the liver is the
source of the increased plasma glycerol found following the oral admin-
istration of sucrose (and other substances). Lastly, the results shown in
Supplementary Fig. 1 that indicate a highly signiﬁcant positive correla-
tion between themean hepatic G3P and plasma glycerol levels amongst
themice clearly supports the ﬁndings that acute changes in hepatic G3P
due to oral administration are directly related to the plasma glycerol
levels. By isolating the liver using the liver perfusion system, we clearly
demonstrated that increased hepatic glycerol synthesis occurs in
double-KO mice following fructose administration.
In the liver, the GLUT2 transport system has been shown to be
required for fructose uptake [27,33]. It is well established that fructose
is rapidly phosphorylated by fructokinase to synthesize fructose
1-phosphate, which is then cleaved to DHAP and glyceraldehyde by
aldolase B. DHAP and glyceraldehyde, (the latter which is converted to
glyceraldehyde 3-phosphate by triokinase) are further metabolized in
the glycolytic or gluconeogenic pathways (Fig. 6). Although we didFig. 6. Schematic model for increased glycerol synthesis in the liver of the double-KOmice follo
themalate-aspartate and glycerophosphate shuttles, operate to translocate cytosolic NADH into
ormGPD is absent, resulting in only a single remaining shuttle for translocating cytosolic NADH
the liver increases glycerol production for the reoxidation of cytosolic NADH. AGC, aspartate-g
nase; DHAP, dihydroxyacetone phosphate; Glu, glutamate; G3P, glycerol 3-phosphate;Mal,mal
oxoglutarate malate carrier; Pyr, pyruvate. See the text for more detailed explanation.not directly evaluate GLUT 2 activity, which could inﬂuence the rate of
fructose uptake into the liver in this study, the rates of glucose and
Lac-plus-Pyr production aswell as that of oxygen consumption reached
similar levels after 10 min of fructose administration (Fig. 3C–E), sug-
gesting that the rates of fructose metabolism were comparable among
all genotypes. As we used mice under fasted conditions in this study
that would have relatively minimal hepatic glycogen reserves, it is un-
likely that the increase in glycerol synthesis induced by fructose admin-
istration resulted from increased glycogenolysis. Therefore, there must
be a mechanism to enhance glycerol synthesis in the liver of double-
KO mice directly dependent on the metabolism of the infused fructose.
In the double-KOmice, administration of fructose led to an increased
cytosolic NADH/NAD+ ratio as indicated by the elevated L/P ratio in the
perfusate (Fig. 3B). This was conﬁrmed by the result that the hepatic
G3P/DHAP ratio was elevated at 30-min perfusion in the double-KO
mice (Supplementary Fig. 2C). This high cytosolic NADH/NAD+ ratio
was due to a lack of both malate-Asp shuttle and glycerophosphate
shuttle activities needed to transport cytosolic NADH reducing
equivalents into the mitochondria. Therefore to reduce accumulated
NADH in the cytosol during fructose metabolism, cytosolic glycerol-3-
phosphate dehydrogenase was still activated (Fig. 6), leading to stimu-
lated glycerol synthesis. Indeed, cytosolic reoxidation by the addition of
Pyr decreased glycerol synthesis in the double-KOmice (Fig. 4A and B).
Moreover, infusion of PMS, which is known to directly oxidize NADH
[31], also reduced hepatic glycerol production. This suggests that the cy-
tosolic NADH/NAD+ ratio was directly responsible for increased hepatic
glycerol synthesis in the double-KO mice. Lastly, these ﬁndings were
further conﬁrmed by showing that an elevated L/P ratio resulted from
the administration of AOA (a transaminase inhibitor that causes
reduced malate-Asp shuttle activity) in the mGPD-KO mice, leading to
enhanced glycerol synthesis (Fig. 4C and D). Therefore, our results
support our conjecture that the liver is a major contributor to the in-
creased plasma glycerol levels observed in the double-KO micewing fructose administration. (A) During fructosemetabolism, two NADH shuttle systems,
themitochondria in the liver of wtmice. In each of the single-KOmice, either AGC (citrin)
into themitochondria. (B)When both NADH shuttles are absent, as in the double-KOmice,
lutamate carrier; αKG, α-ketoglutarate; cGPD, cytosolic glycerol-3-phosphate dehydroge-
ate;mGPD,mitochondrial glycerol-3-phosphate dehydrogenase; OAA, oxaloacetate; OMC,
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NADH/NAD+ ratio as a consequence of carbohydrate metabolism, that
generates hepatic G3P and glycerol owing to the limited potential for re-
oxidation of cytosolic reducing equivalents, leads to elevated plasma
glycerol as well as the likely promotion of its urinary excretion.
In the mGPD-KO mice, the L/P ratio remained constant during fruc-
tose infusion despite a transient increase in glycerol production ob-
served within the ﬁrst 10 min of fructose perfusion (Fig. 3A and B). At
the same time, the rate of glucose production slowly increased, with a
concomitant increase in Lac-plus-Pyr production and inhibition of oxy-
gen consumption in the liver of mGPD-KO mice compared to those of
other genotypes (Fig. 3C–E). Enhanced fructose metabolism in the
liver of mGPD-KO mice would result in an accumulation of NADH in
the cytosol because of the absence of glycerophosphate shuttle activity.
Though we did not check, the hepatic G3P/DHAP ratio could have been
transiently elevated during this time, which might have led to the en-
hanced glycerol synthesis observed in the liver of mGPD-KO mice. In-
creased Lac-plus-Pyr production during the ﬁrst 10 min of fructose
administration indicates that it may have taken time to stimulate the
malate-Asp shuttle (the other NADH transporting system), possibly be-
cause of low oxaloacetate levels. Indeed, once mitochondrial oxidative
phosphorylation was activated, as shown by the change in the rate of
oxygen consumption (Fig. 3E), hepatic glycerol production in mGPD-
KO mice returned to similar levels observed in the wt and citrin-KO
mice.
Our results show that Pyr can correct the disturbances of hepatic
metabolites in the double-KO mice following fructose perfusion
(Supplementary Figs. 2–5). Pyr has been shown to decrease the cytosol-
ic NADH/NAD+ ratio [11] and to increase cellular energy metabolism
[34]. Our previous study also showed that Pyr ameliorates the deﬁcit
in ureogenesis in the perfused liver [16]. Our present results are consis-
tent with the ﬁnding that treatment with Na-Pyr improves the clinical
outcome citrin-deﬁcient patients [35,36]. Although further work is
needed to clarify themechanism(s) in which Pyr improves liver metab-
olism in citrin-deﬁcient patients, our present results further support the
effectiveness of Pyr as a treatment regime.
Our positive ﬁndings of increased urine glycerol and G3P in the
double-KO mice led us to examine the urinary glycerol and G3P excre-
tion of patients with citrin deﬁciency. Urine glycerol and G3P excretion
in the patients from the1–9 year old age groupwere signiﬁcantly higher
than controls, and although the urine glycerol levels of citrin-deﬁcient
patients in the 0–11 month age group were not statistically different
from the control group, more than a third of them showed higher levels
than the upper limit of the control range (407 nmol/mg Cr; Fig. 5B).
Given that the majority of alleles in these patients are null mutations,
there is no obvious correlation between mutation type and urine me-
tabolite level. Formal examination of citrin-deﬁcient patients during ei-
ther an acute clinical presentation, or within the context of a controlled
loading test, may prove to show a greater distinction between citrin-
deﬁcient patients and control subjects. In addition, the NICCD patients
in the 0–11 month old age group, as well as the CTLN2 patients in the
over 10 year old age group, have likely been treated with medications
or nutritional management at the time of sample collection, which
may have led to relatively reduced urine glycerol and G3P levels.Within
this context, the samples collected from the citrin-deﬁcient patients in
the 1–9 year old age group may be the most representative of this pa-
tient population, because despite displaying certain laboratory ﬁndings
[37,38], most of the patients in that age group have no signiﬁcant symp-
toms (with the exception of fatigue) that would require treatment.
A deﬁnitive diagnosis of citrin deﬁciency still relies on the ﬁnding of
biallelic mutations in the SLC25A13 gene. However, front-line tools for
the investigation of patients suspected of having citrin deﬁciency are
still not sufﬁciently informative. In Japan, routine methods of screening
for the most common SLC25A13 gene mutations have failed to identify
the secondmutation in about 15% of suspected citrin-deﬁcient patients,
therefore requiring additional protein investigations [39] or full genesequencing. A plasma or urine glycerol assay in patients suspected of
citrin deﬁciency may be useful, and possibly more informative, if a con-
trolled loading test could be undertaken. Given the observed ﬁnding of
increased plasma glycerol in the double-KO mice in the fasted state, a
loading test using MCT, triheptanoin, or an anapleurotic substrate
such as citrate that does not directly contribute a glycerol molecule dur-
ing its metabolism, could potentially be used to show clear differences
in plasma glycerol levels in citrin-deﬁcient patients without side effects.
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